← Leaderboards
Matthew Memoli
National Institute Of Allergy And Infectious Diseases
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Institute Of Allergy And Infectious Diseases
Same institution · by research overlap
Others in their field
Top investigators on “Morbidity - Disease Rate”
- Marco Pahor · Wake Forest University Health Sciences$29,421,775
- A Benedict Cosimi · Massachusetts General Hospital$17,236,164
- Judith S. Currier · University Of California Los Angeles$11,229,603
- Andrea Jenay Ruff · Johns Hopkins University$10,896,035
- Lucile L Adams-Campbell · Howard University$10,384,616
- Michael K Ong · University Of California Los Angeles$9,898,332
Research focus
Morbidity - Disease RateVirusCollaborationsMortalityEnrollmentResponseNovel VaccinesClinical ResearchPublishingNational Institute Of Allergy And Infectious DiseaseCessation Of LifeImmunityPublic HealthFollow-UpVaccinesPandemic DiseaseAntibodiesImmune ResponsePathogenesisUnited States National Institutes Of HealthFutureUniversitiesChildPersons
Grant awards (22)
Pandemic Influenza Translational Research and novel universal countermeasure development$2,144,187
ZIA · FY2025 · AI · contact PI
Coronavirus Pathogenesis and Broadly Protective Vaccine Development$626,674
ZIA · FY2025 · AI · contact PI
Pandemic Influenza Translational Research and novel universal countermeasure development$981,112
ZIA · FY2024 · AI · contact PI
Coronavirus Pathogenesis and Broadly Protective Vaccine Development$123,282
ZIA · FY2024 · AI · contact PI
Pandemic Influenza Translational Research and novel universal countermeasure development$5,343,633
ZIA · FY2023 · AI · contact PI
Clinical and translational evaluation of vaccination strategies for Zika, Chikungunya, Dengue, Leishmania, Malaria, and other important or emerging vector-borne diseases$1,029,125
ZIA · FY2023 · AI · contact PI
Coronavirus Pathogenesis and Broadly Protective Vaccine Development$718,928
ZIA · FY2023 · AI · contact PI
Pandemic Influenza Translational Research and novel universal countermeasure development$4,672,598
ZIA · FY2022 · AI · contact PI
Coronavirus Pathogenesis and Broadly Protective Vaccine Development$991,645
ZIA · FY2022 · AI · contact PI
Clinical and translational evaluation of vaccination strategies for Zika, Chikungunya, Dengue, Leishmania, Malaria, and other important or emerging vector-borne diseases$548,539
ZIA · FY2022 · AI · contact PI
Pandemic Influenza Translational Research and novel universal countermeasure development$1,338,694
ZIA · FY2021 · AI · contact PI
Clinical and translational evaluation of vector saliva based vaccination strategies for Zika, Chikungunya, Dengue, Leishmania, Malaria, and other important or emerging vector-borne diseases$531,019
ZIA · FY2021 · AI · contact PI
Coronavirus Pathogenesis and Broadly Protective Vaccine Development$331,616
ZIA · FY2021 · AI · contact PI
Coronavirus Pathogenesis and Broadly Protective Vaccine Development$2,010,630
ZIA · FY2020 · AI · contact PI
Pandemic Influenza Translational Research and novel universal countermeasure development$1,406,345
ZIA · FY2020 · AI · contact PI
Clinical and translational evaluation of vector saliva based vaccination strategies for Zika, Chikungunya, Dengue, Leishmania, Malaria, and other important or emerging vector-borne diseases$530,468
ZIA · FY2020 · AI · contact PI
Pandemic Influenza Translational Research; Novel Vaccine and Drug Therapy$2,514,389
ZIA · FY2019 · AI · contact PI
Clinical and translational evaluation of vector saliva based vaccination strategies for Zika and other important or emerging vector-borne diseases$1,058,474
ZIA · FY2019 · AI · contact PI
Pandemic Influenza Translational Research; Novel Vaccine and Drug Therapy$4,294,600
ZIA · FY2018 · AI · contact PI
Clinical and translational evaluation of vector saliva based vaccination strategies for Zika and other important or emerging vector-borne diseases$698,354
ZIA · FY2018 · AI · contact PI
Pandemic Influenza Translational Research and Novel Drug Therapy$5,482,833
ZIA · FY2017 · AI · contact PI
Clinical and translational evaluation of vector saliva based vaccination strategies for Zika and other important or emerging vector-borne diseases$1,453,970
ZIA · FY2017 · AI · contact PI